Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

AstraZeneca PLC (AZN) and Summit Therapeutics Inc (SMMT) are reportedly discussing a $15 billion partnership to license the ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The damage to these cells can cause potential side effects, like fatigue, vomiting and nausea, but it’s important to note ...

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Researchers have identified ways in which chemotherapy can damage healthy cells and found that some drugs can add decades of ...